BCL6 was initially discovered as a transcriptional repressor in B-cell lymphomas, in which it drives the malignant phenotype by binding to hundreds of target genes, and then repressing these genes by recruiting several different chromatin modifying corepressor complexes to repress DNA damage checkpoints and block B-cell terminal differentiation [24]. Here, BCL6 is linked to B-cell non-Hodgkin lymphoma.